Clinical Trials Logo

Macular Telangiectasia Type 2 clinical trials

View clinical trials related to Macular Telangiectasia Type 2.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04907084 Active, not recruiting - Clinical trials for Macular Telangiectasia Type 2

Serine and Fenofibrate Study in Patients With MacTel Type 2

SAFE
Start date: April 7, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms. Participants will be randomly assigned to one of the following treatment groups: serine 200 mg/kg/day, serine 400 mg/kg/day, fenofibrate 160 mg/day, both serine 200 mg/kg/day and fenofibrate 160 mg/day, both serine 400 mg/kg/day and fenofibrate 160 mg/day, or no treatment (control group). Serum deoxysphingolipid levels will be used as the primary outcome, and safety will be evaluated. The participants will be followed for 10 weeks, with visits at Screening, Week 0, 3, 6 and 10.